Cure8 research brief
Postoperative endoscopic recurrence is common after ileocolonic resection for Crohn’s disease; this study suggests biologic drugs started after surgery are linked to lower recurrence rates. Knowing which biologics perform well in routine care can help guide postoperative prevention strategies.
Adult Crohn’s patients post-ileocolonic resection, clinicians managing postoperative prophylaxis, researchers in IBD therapeutics.
This study reports a retrospective, population-based cohort of adults with Crohn’s disease who had ileocolonic resection with primary anastomosis.
Researchers compared real-world effectiveness of biologic prophylaxis (TNF antagonists, ustekinumab, vedolizumab) versus no biologic treatment for preventing endoscopic postoperative recurrence within 18 months, using the modified Rutgeerts score as the main outcome.
In weighted analyses accounting for clinical risk factors, any biologic prophylaxis was associated with substantially lower odds of endoscopic recurrence compared with no treatment. Vedolizumab showed lower odds of recurrence than ustekinumab in this cohort; differences versus TNF antagonists were not statistically significant.
These findings come from routine-care data in a single geographic region (Calgary Health Zone, Canada) and reflect associations rather than randomized comparisons. Individual decisions about postoperative prophylaxis should still be made with clinicians, considering prior drug exposure, infection risk, and patient preferences.
Observational design using inverse probability weighting reduces but does not eliminate confounding. The source is an abstract-level report from the American Journal of Gastroenterology; findings should be interpreted as study observations rather than definitive causal proof.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Patients and clinicians are interested in whether combining two targeted biologic therapies can induce stronger endoscopic healing for people with difficult-to-treat Crohn's disease, and whether benefit can be maintained...
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
